Robert Holmes, DO
Rheumatology · Pollocksville, NCNPI 1053496349
Payments from drug & device makers
Across 1,366 payments — averaging $157.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$76K
- Amgen$38K
- Regeneron Healthcare Solutions, Inc.$32K
- Mallinckrodt Hospital Products Inc.$32K
- Bristol Myers Squibb$22K
- Sanofi$3K
- plus $11K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 212 | $76,011 |
| Amgen(2 entities) | 279 | $38,303 |
| Regeneron Healthcare Solutions, Inc. | 53 | $32,143 |
| Mallinckrodt Hospital Products Inc. | 66 | $32,125 |
| Bristol Myers Squibb | 31 | $22,498 |
| Sanofi | 8 | $2,943 |
| Novartis | 94 | $1,678 |
| Pfizer | 166 | $1,536 |
| Lilly USA, LLC | 92 | $1,447 |
| UCB, Inc. | 65 | $1,112 |
| GSK | 63 | $908 |
| Johnson & Johnson | 30 | $756 |
| AstraZeneca | 43 | $745 |
| Aurinia Pharma U.S., Inc. | 51 | $702 |
| Radius Health, Inc. | 24 | $451 |
| Boehringer Ingelheim | 21 | $366 |
| E.r. Squibb & Sons, L.L.C. | 17 | $299 |
| Genentech USA, Inc. | 11 | $164 |
| Bayer | 17 | $150 |
| ANI Pharmaceuticals, Inc. | 6 | $140 |
| Fresenius Kabi USA, LLC | 5 | $122 |
| Octapharma USA, Inc. | 2 | $42 |
| Abbott | 2 | $29 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Mallinckrodt Enterprises LLC | 1 | $22 |
| Sequel Med Tech, LLC | 1 | $21 |
| Edwards Lifesciences | 1 | $20 |
| Pharming Healthcare, Inc. | 1 | $19 |
| Medtronic | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $12 |
How this compares
$214,822 in reported general payments places this provider in the 85th percentile of 210 rheumatology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Pollocksville
- Laura SchanbergDurham$6.9M
- Rakesh PatelSalisbury$4M
- Jane BoxCharlotte$3.9M
- Gordon LamCharlotte$3.5M
- David SnowDelco$3.4M
- Alireza NamiCharlotte$3.1M
- Tauseef SyedGreensboro$1.7M
- Michael HershfieldDurham$1.5M
- Ralph SnydermanDurham$1.3M
- Megan ClowseDurham$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.